Anti‐epidermal growth factor receptor therapy for glioblastoma in adults

Review (9 studies) found no evidence of benefit in overall survival with use of anti‐EGFR therapy in first‐line or recurrent setting [HR 0.89, 95% CI 0.76-1.04; 3 RCTs, n=1000, moderate‐certainty evidence; & 0.79; 0.51-1.21, 4 RCTs, n=489, low‐certainty evidence, respectively).


Cochrane Database of Systematic Reviews